Search hospitals > Michigan > Wyoming
Gastroenterology Associates of Western Michigan, P.L.C.
Claim this profileWyoming, Michigan 49519
Global Leader in Crohn's Disease
Global Leader in Ulcerative Colitis
Conducts research for Colitis
Conducts research for Gastroparesis
Conducts research for Gastric Stasis
54 reported clinical trials
1 medical researcher
Summary
Gastroenterology Associates of Western Michigan, P.L.C. is a medical facility located in Wyoming, Michigan. This center is recognized for care of Crohn's Disease, Ulcerative Colitis, Colitis, Gastroparesis, Gastric Stasis and other specialties. Gastroenterology Associates of Western Michigan, P.L.C. is involved with conducting 54 clinical trials across 53 conditions. There are 1 research doctors associated with this hospital, such as Allan Coates, MD.Top PIs
Clinical Trials running at Gastroenterology Associates of Western Michigan, P.L.C.
Crohn's Disease
Ulcerative Colitis
Colitis
Nonalcoholic Steatohepatitis
Type 2 Diabetes
Non-alcoholic Fatty Liver Disease
Crohn's disease
Gastrointestinal Diseases
Congenital Hepatobiliary Disorders
Outpatient Colonoscopy
Vedolizumab
for Ulcerative Colitis and Crohn's Disease
Ulcerative Colitis (UC) and Crohn's Disease (CD) are long-term conditions in the gut that can cause diarrhea, swelling (inflammation), bleeding from the anus, and belly pain. The main aim of this study is to check for how many participants with UC and CD signs and symptoms disappear after 3.5 months (14 weeks) of treatment with Vedolizumab (this is called remission). Participants will be treated with Vedolizumab for approximately 1 year (50 weeks). During the first 1.5 months (6 weeks), participants will receive Vedolizumab as an infusion in the vein (called intravenously). After this, participants will receive Vedolizumab as an injection under the skin (called subcutaneously) for the rest of the treatment. Participants for whom the treatment does not seem to work well after 3.5 months (14 weeks) will stop treatment with Vedolizumab and can change to another treatment and also there will be additional required visits at 6 months (26 weeks) and at 1 year (52 weeks). All participants will be checked again 4.5 months (18 weeks) after their last treatment with Vedolizumab. During the study, participants will visit their study clinic several times.
Recruiting3 awards Phase 42 criteria
SAR442970
for Crohn's Disease
This is a phase 2b, randomized, double-blind, 3-arm study for the treatment of Crohn's disease. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Crohn's disease. The total study duration is up to 168 weeks, with a treatment period of up to 158 weeks including an open-label (OL) long-term extension (LTE) period of up to 104 weeks for eligible participants
Recruiting0 awards Phase 21 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Gastroenterology Associates of Western Michigan, P.L.C.?
Gastroenterology Associates of Western Michigan, P.L.C. is a medical facility located in Wyoming, Michigan. This center is recognized for care of Crohn's Disease, Ulcerative Colitis, Colitis, Gastroparesis, Gastric Stasis and other specialties. Gastroenterology Associates of Western Michigan, P.L.C. is involved with conducting 54 clinical trials across 53 conditions. There are 1 research doctors associated with this hospital, such as Allan Coates, MD.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.